Results 111 to 120 of about 35,554 (229)

Synthesis and Biological Activity of some New Pyrimidines

, 1989
S. EL-BAHAIB, M. G. ASSY
openalex   +1 more source

Design, Synthesis, Bioevaluation, and Bioinformatics Study of 5‐Benzylidene Hydantoin Derivatives as Novel Tyrosine Kinase Inhibitors

ChemistryOpen, EarlyView.
A series of 5‐benzylidene hydantoin derivatives is synthesized and evaluated against eight receptor tyrosine kinases (RTKs). Several compounds show selective and moderate inhibition of human epidermal growth factor receptor 2 (HER2). Molecular docking reveals key interactions with the HER2 active site, highlighting the potential of 5‐benzylidene ...
Muhammad Naufal, Elvira Hermawati, Ade Danova, Ika Wiani Hidayat, Jamaludin Al‐Anshori   +4 more
wiley   +1 more source

Pyrimidine [PDF]

, 2020
openaire   +1 more source

Inhibition of histamine release by purine and pyrimidine derivatives

, 1982
Kazuhiro Shimamura, Masahiro Nishibori, Hiroshi Yokoyama, Kohji Tsutsumi, Kiyomi Saeki   +4 more
openalex   +1 more source

Design, Synthesis, Cytotoxicity Assessment, and Molecular Docking of Novel Triazolopyrimidines as Potent Cyclin‐Dependent Kinase 4 Inhibitors

ChemistryOpen, EarlyView.
A novel series of 1,5‐dihydro‐[1,2,4]triazolo[4,3‐a]pyrimidines (5a–g) is synthesized and evaluated as potential CDK4 inhibitors. Compounds 5c and 5d exhibit strong cytotoxicity toward HepG2 and MCF‐7 cells with IC50 ≈ 1–2 µM, comparable to doxorubicin.
Tariq Z. Abolibda, Sami A. Al‐Hussain, Basant Farag, Mohamed El‐Naggar, Magdi E. A. Zaki, Emad S. A. Alhazmi, Adel S. M. Almohammadi, Sobhi M. Gomha   +7 more
wiley   +1 more source

Synthesis of Pyrido[2,3‐d]Azolopyrimidinones: Design and Epidermal Growth Factor Receptor‐Targeted Molecular Docking Toward Novel Anticancer Leads

ChemistryOpen, EarlyView.
New pyrido[2,3‐d]azolopyrimidinones were synthesized and evaluated as potent EGFR‐targeted anticancer leads. Molecular docking and cytotoxicity studies revealed strong receptor binding and submicromolar activity, highlighting this scaffold as a promising framework for future targeted drug development.
Sobhi M. Gomha, Sami A. Al‐Hussain, Basant Farag, AbdElAziz A. Nayl, Wesam Hussein, Abdelwahed R. Sayed, Magdi E. A. Zaki   +6 more
wiley   +1 more source

The ketogenic diet alters microbiome‐metabolome profiles to improve West syndrome therapy

Pediatric Investigation, EarlyView.
The ketogenic diet alleviates West syndrome by reshaping gut microbiota (increasing Bacteroides, Parabacteroides, and reducing Escherichia and Bifidobacterium), and modulating metabolites—including anticonvulsant lipids (e.g., capric acid), suppressed harmful lipids (e.g., 2‐methylbutyroylcarnitine), and amino acids and analogs (e.g., 3‐sulfinoalanine)—
Gan Xie, Qian Zhou, Jianxiang Liao, Yuejie Zheng, Wenjian Wang, Kunling Shen   +5 more
wiley   +1 more source

Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2′-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3′-5′-Cyclic Phosphate Ester Prodrug of 2′-Deoxy-2′-Spirooxetane Uridine Triphosphate Useful for HCV Inhibition

, 2016
Tim H. M. Jonckers, Abdellah Tahri, Leen Vijgen, Jan Martin Berke, Sophie Lachau‐Durand, Bart Stoops, Jan Snoeys, Laurent Leclercq, Lotke Tambuyzer, Tse‐I Lin, Kenny Simmen, Pierre Raboisson   +11 more
openalex   +1 more source

Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II—Benzimidazole Derivatives [PDF]

, 2022
Mariola Stypik, Stanisław Michałek, Nina Orłowska, Marcin Zagozda, Maciej Dziachan, Martyna Banach, Paweł Turowski, Paweł Gunerka, Daria Zdżalik-Bielecka, Aleksandra Stańczak, Urszula Kędzierska, Krzysztof Mulewski, Damian Smuga, Wioleta Maruszak, Lidia Gurba-Bryśkiewicz, Arkadiusz Leniak, Wojciech Pietruś, Zbigniew Ochal, Mateusz Mach, Beata M. Zygmunt, Jerzy Pieczykolan, Krzysztof Dubiel, Maciej Wieczorek   +22 more
openalex   +1 more source

The continuing significance of chiral agrochemicals

Pest Management Science, Volume 81, Issue 4, Page 1697-1716, April 2025.
In the time frame 2018–2023, around 43% of the 35 chiral agrochemicals introduced to the market (herbicides, fungicides, insecticides, acaricides, and nematicides) contain one or more stereogenic centers in the molecule, and almost 69% of them have been marketed as racemic mixtures of enantiomers or stereoisomers.
Peter Jeschke
wiley   +1 more source